MARKET

PALI

PALI

Palisade Bio Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.900
+0.020
+0.52%
After Hours: 3.830 -0.07 -1.79% 18:17 05/18 EDT
OPEN
3.830
PREV CLOSE
3.880
HIGH
3.940
LOW
3.700
VOLUME
712.35K
TURNOVER
--
52 WEEK HIGH
16.02
52 WEEK LOW
3.000
MARKET CAP
11.24M
P/E (TTM)
-0.4410
1D
5D
1M
3M
1Y
5Y
Palisade Bio Granted Notice Of Allowance For U.S. Patent Titled 'COMPOSITIONS FOR THE TREATMENT OF AUTODIGESTION'
https://patentcenter.uspto.gov/#!/applications/15707943/ifw/docs
Benzinga · 1d ago
74 Biggest Movers From Friday
Gainers MoSys, Inc. (NASDAQ: MOSY) shares climbed 50.5% to settle at $4.35 on Friday. MoSys, last week, reported a loss for its first quarter.
Benzinga · 1d ago
DASH, PALI, HYRE and CRMD among midday movers
Gainers: MoSys (MOSY) +43%.HyreCar (HYRE) +41%.Vivint Smart Home (VVNT) +26%.DoorDash (DASH) +26%.Intrusion (INTZ) +26%.One Stop Systems (OSS) +24%.LifeMD (LFMD) +24%.Atea Pharmaceuticals (AVIR) +24%.Cricut (CRCT) +23%.SemiLEDs (LEDS) +20%.Losers: CorMedix...
Seekingalpha · 4d ago
Thinking about buying stock in Sundial Growers, Palisade Bio, Ocugen, Farmmi, or Bank of America?
, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SNDL, PALI, OCGN, FAMI, and BAC.
PR Newswire - PRF · 5d ago
Palisade Bio Stock Shoots Up On FDA Fast Track Tag For LB1148 For Reduction of Post-Operative Adhesions
Benzinga · 5d ago
AMC, OCGN, SONO and HRTX among premarket gainers
Palisade Bio (PALI) +36% on FDA's fast track designation for LB1148.Fuel Tech (FTEK) +21% on Q1 results.Lianluo Smart (LLIT) +20%.Celyad Oncology SA (CYAD) +20%.Vertex Energy (VTNR) +18% on Q1 results.InnSuites Hospitality Trust (IHT)
Seekingalpha · 5d ago
Palisade Bio shares surge on LB1148 FDA fast track status
Palisade Bio (PALI) shares climb more than 30% during premarket trading after the U.S. FDA granted "Fast Track" designation to the company's LB1148 treatment being developed as an oral treatment to reduce
Seekingalpha · 5d ago
12 Health Care Stocks Moving In Thursday's Pre-Market Session
 
Benzinga · 5d ago
More
Forecast
Actual (K USD)
Estimate (K USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of PALI. Analyze the recent business situations of Palisade Bio Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Price Target
The average PALI stock price target is 26.00 with a high estimate of 26.00 and a low estimate of 26.00.
EPS
Institutional Holdings
Institutions: 40
Institutional Holdings: 159.45K
% Owned: 5.53%
Shares Outstanding: 2.88M
TypeInstitutionsShares
Increased
2
55.91K
New
3
21.54K
Decreased
2
7.48K
Sold Out
2
27.92K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.42%
Pharmaceuticals & Medical Research
+0.07%
Key Executives
Chairman/Director
James Neal
President/Chief Operating Officer
Matthew Kalnik
Other
David Recker
Chief Executive Officer/Chief Financial Officer/Chief Accounting Officer
Dane Saglio
Chief Executive Officer/Director
Thomas Hallam
Director
Stephanie Diaz
Director
Mary Gray
Director
Robert Trenschel
Director
Don Williams
Independent Director
Cristina Csimma
Independent Director
Scott Ogilvie
Independent Director
Sandford Smith
Independent Director
Binxian Wei
Independent Director
Stanley Westreich
No Data
About PALI
Palisade Bio, Inc, formerly Seneca Biopharma, Inc., is a biopharmaceutical company. The Company is focused on developing therapies that helps patients with acute and chronic gastrointestinal problems from post-operative digestive enzyme damage. Its product candidate, LB1148, is a Phase III-ready protease inhibitor which is developed to reduce abdominal adhesions and help restore bowel function following surgery. It is engaged in developing oral product candidates to treat conditions driven by protease (intestinal digestive enzymes) escaping the intestines, including surgical problems and inflammatory conditions. Its LB1148 is an oral formulation of a serine protease inhibitor designed to neutralize the activity of potent digestive proteases released from the gut during surgery.

Webull offers kinds of Palisade Bio Inc stock information, including NASDAQ:PALI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PALI stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PALI stock methods without spending real money on the virtual paper trading platform.